| Lenalidomide |
|
|
|
| No. of Cycles Administered |
428 |
267 |
695 |
| Median % of Targeted Dose (Range) |
80% (12–100) |
80% (19–100) |
80% (12–100) |
| No. of Patients with Reductions |
22 (65%) |
12 (63%) |
34 (64%) |
| Total Reductions |
41 |
26 |
67 |
| Reasons for Reductions |
|
|
|
| Neutropenia |
23 |
13 |
36 |
| Thrombocytopenia |
1 |
0 |
1 |
| Nonblistering rash |
3 |
6 |
9 |
| Grade 3+ Adverse Event |
8 |
0 |
8 |
| Other |
6 |
7 |
13 |
| Cyclophosphamide |
|
|
|
| No. of Cycles Administered |
219 |
171 |
390 |
| Median % of Targeted Dose (Range) |
96% (0–102) |
100% (11–100) |
96% (0–102) |
| No. of Patients with Reductions |
19 (56%) |
9 (47%) |
28 (53%) |
| Total Reductions |
28 |
12 |
40 |
| Reasons for Reductions |
|
|
|
| Neutropenia |
16 |
12 |
28 |
| Grade 3 + Adverse Event |
6 |
0 |
6 |
| Other |
6 |
0 |
6 |
| Dexamethasone |
|
|
|
| No. of Cycles Administered |
362 |
249 |
611 |
| Median % of Targeted Dose (Range) |
75% (0–100) |
50% (0–100) |
75% (0–100) |
| No. of Patients with Reductions |
12 (35%) |
11 (58%) |
23 (43%) |
| Total Reductions |
25 |
29 |
54 |
| Reasons for Reductions |
|
|
|
| Hyperglycemia |
0 |
6 |
6 |
| Muscle Weakness |
2 |
4 |
6 |
| Confusion/Mood Alteration |
14 |
1 |
15 |
| Insomnia |
4 |
3 |
7 |
| Other |
5 |
15 |
14 |
